

Martin Busch

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6171017/publications.pdf>

Version: 2024-02-01

25
papers

918
citations

567281
15
h-index

501196
28
g-index

32
all docs

32
docs citations

32
times ranked

1707
citing authors

#	ARTICLE	IF	CITATIONS
1	Heart-Type Fatty Acid Binding Protein, Cardiovascular Outcomes, and Death: Findings From the German CKD Cohort Study. American Journal of Kidney Diseases, 2022, , .	1.9	0
2	Organ Manifestation and Systematic Organ Screening at the Onset of Inflammatory Rheumatic Diseases. Diagnostics, 2022, 12, 67.	2.6	2
3	Antidiabetic Therapy and Rate of Severe Hypoglycaemia in Patients with Type 2 Diabetes and Chronic Kidney Disease of Different Stages â€” A Follow-up Analysis of Health Insurance Data from Germany. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 821-830.	1.2	4
4	Spectrum and dosing of urate-lowering drugs in a large cohort of chronic kidney disease patients and their effect on serum urate levels: a cross-sectional analysis from the German Chronic Kidney Disease study. CKJ: Clinical Kidney Journal, 2021, 14, 277-283.	2.9	1
5	Rituximab in Membranous Nephropathy. Kidney International Reports, 2021, 6, 881-893.	0.8	39
6	Rate, Factors, and Outcome of Delayed Graft Function After Kidney Transplantation of Deceased Donors. Transplantation Proceedings, 2021, 53, 1454-1461.	0.6	8
7	Association of the metabolic syndrome with mortality and major adverse cardiac events: A large chronic kidney disease cohort. Journal of Internal Medicine, 2021, 290, 1219-1232.	6.0	27
8	Novel Biomarkers in Patients with Chronic Kidney Disease: An Analysis of Patients Enrolled in the GCKD-Study. Journal of Clinical Medicine, 2020, 9, 886.	2.4	15
9	Mucosal-Associated Invariant T Cells Redistribute to the Peritoneal Cavity During Spontaneous Bacterial Peritonitis and Contribute to Peritoneal Inflammation. Cellular and Molecular Gastroenterology and Hepatology, 2020, 9, 661-677.	4.5	24
10	FP155PREDICTORS OF RENAL INVOLVEMENT IN ANCA ASSOCIATED VASCULITIS. Nephrology Dialysis Transplantation, 2018, 33, i81-i82.	0.7	0
11	Blood pressure control in chronic kidney disease: A cross-sectional analysis from the German Chronic Kidney Disease (GCKD) study. PLoS ONE, 2018, 13, e0202604.	2.5	20
12	Glycaemic control and antidiabetic therapy in patients with diabetes mellitus and chronic kidney disease â€” cross-sectional data from the German Chronic Kidney Disease (GCKD) cohort. BMC Nephrology, 2016, 17, 59.	1.8	18
13	Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort. Nephrology Dialysis Transplantation, 2015, 30, 441-451.	0.7	132
14	Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates. Kidney International, 2015, 88, 1411-1418.	5.2	23
15	Heart Failure in a Cohort of Patients with Chronic Kidney Disease: The GCKD Study. PLoS ONE, 2015, 10, e0122552.	2.5	18
16	Rituximab for the second- and thirdline therapy of idiopathic membranous nephropathy: a prospective single center study using a new treatment strategy. Clinical Nephrology, 2013, 80, 105-113.	0.7	13
17	Advanced Glycation End Products and Î²₂-Microglobulin as Predictors of Carpal Tunnel Syndrome in Hemodialysis Patients. Blood Purification, 2012, 34, 3-9.	1.8	9
18	The German Chronic Kidney Disease (GCKD) study: design and methods. Nephrology Dialysis Transplantation, 2012, 27, 1454-1460.	0.7	127

#	ARTICLE	IF	CITATIONS
19	Advanced glycation end products and the kidney. European Journal of Clinical Investigation, 2010, 40, 742-755.	3.4	184
20	Vitamin B ₆ Metabolism in Chronic Kidney Disease – Relation to Transsulfuration, Advanced Glycation and Cardiovascular Disease. Nephron Clinical Practice, 2010, 114, c38-c46.	2.3	24
21	Serum Levels of the Advanced Glycation End Products N ^ε -Carboxymethyllysine and Pentosidine Are Not Influenced by Treatment with the Angiotensin Receptor II Type 1 Blocker Irbesartan in Patients with Type 2 Diabetic Nephropathy and Hypertension. Nephron Clinical Practice, 2008, 108, c291-c297.	2.3	18
22	The Advanced Glycation End Product N ^ε -Carboxymethyllysine Is Not a Predictor of Cardiovascular Events and Renal Outcomes in Patients With Type 2 Diabetic Kidney Disease and Hypertension. American Journal of Kidney Diseases, 2006, 48, 571-579.	1.9	59
23	Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites, and the C-reactive protein. Kidney International, 2004, 66, 338-347.	5.2	108
24	Are advanced glycation end products cardiovascular risk factors in patients with CRF?. American Journal of Kidney Diseases, 2003, 41, S52-S56.	1.9	29
25	Validated capillary gas chromatographic–mass spectrometric assay to determine 2-methylcitric acid I and II levels in human serum by using a pulsed splitless injection procedure. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2002, 775, 215-223.	2.3	6